Prostate Cancer Screening and the Management of Clinically Localized Disease

Overview

Journal BMJ

Specialty General Medicine

Date 2013 Jan 31

PMID 23360718

Citations 32

Authors

Timothy J Wilt

Hashim U Ahmed

Affiliations

Soon will be listed here.

Citing Articles

Innovations and Emerging Trends in Prostate Cancer Management: A Literature Review.

Ibraheem N, Abdelglil M, Wanees A, Aosmali A, Shahid M, Mithany R Cureus. 2024; 16(11):e73128.

PMID: 39512805 PMC: 11542590. DOI: 10.7759/cureus.73128.

Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors.

Orozco-Moreno M, Visser E, Hodgson K, Hipgrave Ederveen A, Bastian K, Goode E Glycobiology. 2023; 33(12):1155-1171.

PMID: 37847613 PMC: 10876042. DOI: 10.1093/glycob/cwad085.

Does including histological outcomes in a multiparametric MRI report improve prostate biopsy decision making?.

Stevens W, Parchment-Smith C, Adiotomre E, Hulson O, Khan A, Melling P Br J Radiol. 2023; 96(1144):20220395.

PMID: 36802746 PMC: 10078883. DOI: 10.1259/bjr.20220395.

PROState Pathway Embedded Comparative Trial: The IP3-PROSPECT study.

Bass E, Klimowska-Nassar N, Sasikaran T, Day E, Fiorentino F, Sydes M Contemp Clin Trials. 2021; 107:106485.

PMID: 34139356 PMC: 8451266. DOI: 10.1016/j.cct.2021.106485.

Making a case "for" focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials.

Wang A, Lebastchi A, OConnor L, Ahdoot M, Mehralivand S, Yerram N World J Urol. 2021; 39(3):729-739.

PMID: 33388878 DOI: 10.1007/s00345-020-03525-0.

References

Nguyen P, Je Y, Schutz F, Hoffman K, Hu J, Parekh A . Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011; 306(21):2359-66. DOI: 10.1001/jama.2011.1745. View

Lord S, Staub L, Bossuyt P, Irwig L . Target practice: choosing target conditions for test accuracy studies that are relevant to clinical practice. BMJ. 2011; 343:d4684. DOI: 10.1136/bmj.d4684. View

Welch H, Albertsen P . Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009; 101(19):1325-9. PMC: 2758309. DOI: 10.1093/jnci/djp278. View

Chou R, Croswell J, Dana T, Bougatsos C, Blazina I, Fu R . Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011; 155(11):762-71. DOI: 10.7326/0003-4819-155-11-201112060-00375. View

Ahmed H, Hu Y, Carter T, Arumainayagam N, Lecornet E, Freeman A . Characterizing clinically significant prostate cancer using template prostate mapping biopsy. J Urol. 2011; 186(2):458-64. DOI: 10.1016/j.juro.2011.03.147. View

Welch H, Schwartz L, Woloshin S . Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst. 2005; 97(15):1132-7. DOI: 10.1093/jnci/dji205. View

Wilt T, Thompson I . Clinically localised prostate cancer. BMJ. 2006; 333(7578):1102-6. PMC: 1661729. DOI: 10.1136/bmj.39022.423588.DE. View

van der Kwast T . The trade-off between sensitivity and specificity of clinical protocols for identification of insignificant prostate cancer. Eur Urol. 2012; 62(3):469-71. DOI: 10.1016/j.eururo.2012.04.017. View

Relton C, Torgerson D, OCathain A, Nicholl J . Rethinking pragmatic randomised controlled trials: introducing the "cohort multiple randomised controlled trial" design. BMJ. 2010; 340:c1066. DOI: 10.1136/bmj.c1066. View

10.

Moyer V . Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157(2):120-34. DOI: 10.7326/0003-4819-157-2-201207170-00459. View

11.

Donovan J, Hamdy F, Neal D, Peters T, Oliver S, Brindle L . Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess. 2003; 7(14):1-88. DOI: 10.3310/hta7140. View

12.

Ganz P, Barry J, Burke W, Col N, Corso P, Dodson E . National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med. 2012; 156(8):591-5. PMC: 4774889. DOI: 10.7326/0003-4819-156-8-201204170-00401. View

13.

Cooperberg M, Lubeck D, Meng M, Mehta S, Carroll P . The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004; 22(11):2141-9. PMC: 2997214. DOI: 10.1200/JCO.2004.10.062. View

14.

Dennert G, Zwahlen M, Brinkman M, Vinceti M, Zeegers M, Horneber M . Selenium for preventing cancer. Cochrane Database Syst Rev. 2011; (5):CD005195. PMC: 3692366. DOI: 10.1002/14651858.CD005195.pub2. View

15.

Ahmed H, Hindley R, Dickinson L, Freeman A, Kirkham A, Sahu M . Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol. 2012; 13(6):622-32. PMC: 3366323. DOI: 10.1016/S1470-2045(12)70121-3. View

16.

Wilt T, Brawer M, Jones K, Barry M, Aronson W, Fox S . Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012; 367(3):203-13. PMC: 3429335. DOI: 10.1056/NEJMoa1113162. View

17.

Dahabreh I, Chung M, Balk E, Yu W, Mathew P, Lau J . Active surveillance in men with localized prostate cancer: a systematic review. Ann Intern Med. 2012; 156(8):582-90. DOI: 10.7326/0003-4819-156-8-201204170-00397. View

18.

Sanda M, Dunn R, Michalski J, Sandler H, Northouse L, Hembroff L . Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358(12):1250-61. DOI: 10.1056/NEJMoa074311. View

19.

Onik G, Miessau M, Bostwick D . Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management. J Clin Oncol. 2009; 27(26):4321-6. DOI: 10.1200/JCO.2008.20.3497. View

20.

Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark J, Busch C . Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011; 364(18):1708-17. DOI: 10.1056/NEJMoa1011967. View